New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including those whose tumors progressed